Merck KGaA Plumps For Reinvention To Refuel R&D
Aim Is To Launch A New Product Every 1.5 Years
The German group says that 50% of future new launches are expected to come from externally sourced assets to take the strain of its organic discovery engine.
You may also be interested in...
Merck KGaA’s Oncology Sales And Pipeline Updates Dominate Q3 Earnings
The German firm’s oncology franchise grew to more than €400m in the third quarter as sales of Bavencio doubled, while anticancer partnerships and pipeline updates drew interest.
Merck KGaA Ties Up Chord To Advance Cladribine Rare Disease Programs
Merck will develop Chord’s lead drug candidate, an oral version of cladribine, for the treatment of neuromyelitis optica spectrum disorders and generalized myasthenia gravis.
Merck KGaA Bags Exclusive Rights To Develop, Sell Debiopharm’s Xevinapant
Germany’s Merck has licensed exclusive rights to develop and sell Debiopharm’s potential first-in-class inhibitor of apoptosis proteins (IAP) antagonist, targeting head and neck cancers.